Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881107077222v1
21/8/815    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by James, L.
Right arrow Articles by Paton, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by James, L.
Right arrow Articles by Paton, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on November 1, 2007
Journal of Psychopharmacology, Vol. 21, No. 8, 815-819 (2007)
DOI: 10.1177/0269881107077222

Informing patients of the teratogenic potential of mood stabilizing drugs: a case note review of the practice of psychiatrists

Laraine James

Oxleas NHS Foundation Trust, Dartford, Kent, UK

Thomas R.E. Barnes

Department of Psychological Medicine, Imperial College, London, UK

Paul Lelliott

Royal College of Psychiatrists Research Unit, London, UK

David Taylor

South London and Maudsley NHS Foundation Trust, London, UK

Carol Paton

Oxleas NHS Foundation Trust, Dartford, Kent, UK, carol.paton{at}oxleas.nhs.uk

Lithium, carbamazepine and valproate are established human teratogens. Women of childbearing potential who are prescribed these drugs should be informed of their teratogenic potential and advised of the need for adequate contraception and the protective role of folate. We reviewed the clinical records of all women of childbearing age in long-term contact with one specialist mental health Trust providing services for a total population of 750 000. 0ne hundred and thirty eight (16%) of 837 women of childbearing age were prescribed one or more of these drugs. There was documented evidence that 29 (21%) of these women had been informed about teratogenicity and that 33 (24%) had been advised about contraception. Fourteen women (10%) had a confirmed pregnancy while taking lithium, carbamazepine or valproate; eight had a complication of pregnancy. If prescribing practice in this large mental health Trust were typical of the UK, between 7000 and 11 000 women of childbearing potential would be prescribed lithium, carbamazepine or valproate by psychiatrists without documented discussion of the risks.

Key Words: lithium • carbamazepine • valproate • folate • mood stabilizer • pregnancy • teratogenicity • women


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
C. Paton
Prescribing in pregnancy
The British Journal of Psychiatry, May 1, 2008; 192(5): 321 - 322.
[Abstract] [Full Text] [PDF]